A Boston biotech's decision to pause a Duchenne muscular dystrophy study has resulted in a significant stock drop.

On Tuesday, the FDA accepted for review Capricor Therapeutics Inc’s (NASDAQ:CAPR) Biologics License Application for ...

PepGen halts its Phase 2 CONNECT2 trial for PGN-EDO51 in DMD to assess 10 mg/kg cohort data, while advancing FREEDOM-DM1 studies in myotonic dystrophy.

CureDuchenne, a global leader in Duchenne muscular dystrophy (DMD) research, care, and advocacy, has announced a landmark ...

Researchers, physicians, families and affected patients view Duchenne muscular dystrophy (DMD) as a neuromuscular condition. Children are diagnosed during the first years of life because they have ...

There is a broad consensus in the medical community in support of Duchenne newborn screening and we in Connecticut are hoping ...

Duchenne muscular dystrophy causes progressive muscle degeneration and weakness, but physical exercise should still be part of a comprehensive treatment strategy. Duchenne muscular dystrophy (DMD ...

The Food and Drug Administration (FDA) has granted Priority Review to the Biologics License Application (BLA) for deramiocel (CAP-1002) for the treatment ...

Duchenne muscular dystrophy (DMD) is a rare neurological condition that causes severe muscle weakness and intellectual disability. DMD is an inherited (passed down) disorder. The condition is ...

In an international collaboration, researchers have made an important breakthrough in the therapeutic delivery of microRNAs ...

Activities of daily life, education, and employment were areas of difficulty in the transition to adulthood for patients with ...

Entrada Therapeutics gains FDA clearance for its Phase 1b ELEVATE-44-102 study, evaluating ENTR-601-44 in adult Duchenne ...